Recanalization and Clinical Outcome of Occlusion Sites at Baseline CT Angiography in the Interventional Management of Stroke III Trial

Demchuk, Andrew M.; Goyal, Mayank; Yeatts, Sharon D.; Carrozzella, Janice; Foster, Lydia D; Qazi, Emmad; Hill, Michael D.; Jovin, Tudor G; Ribó, Marc; Yan, Bernard; Zaidat, Osama O.; Frei, Donald; Kummer, Rüdiger von; Cockroft, Kevin M.; Khatri, Pooja; Liebeskind, David S; Tomsick, Thomas A.; Palesch, Yuko Y.; Broderick, Joseph P.

doi:10.1148/radiol.14132649

Cited by 140 publications

(114 citation statements)

References 23 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…20,21 In fact, a significantly higher rate of recanalization in proximal occlusions with endovascular therapy were observed in subgroup analyses of patients who underwent screening for LVO in IMS III, and ICA T-or L-type and tandem ICA and M1 occlusions demonstrated a trend toward better outcome with endovascular treatment. 22,23 Two prior RCTs, Trevo versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2) and SWIFT, demonstrated significantly higher recanalization rates associated with stent retriever devices compared to the early generation Merci Retriever (Concentric Medical, Fremont, CA).…”

Section: Resultsmentioning

confidence: 99%

Endovascular vs medical management of acute ischemic stroke

et al. 2015

View full text Add to dashboard Cite

Objective: To compare the outcomes between endovascular and medical management of acute ischemic stroke in recent randomized controlled trials (RCT).Methods: A systematic literature review was performed, and multicenter, prospective RCTs published from January 1, 2013, to May 1, 2015, directly comparing endovascular therapy to medical management for patients with acute ischemic stroke were included. Meta-analyses of modified Rankin Scale (mRS) and mortality at 90 days and symptomatic intracranial hemorrhage (sICH) for endovascular therapy and medical management were performed. Conclusions: This meta-analysis provides strong evidence that endovascular intervention combined with medical management, including IV tissue plasminogen activator for eligible patients, improves the outcomes of appropriately selected patients with acute ischemic stroke in the setting of LVO.

show abstract

Section: Resultsmentioning

confidence: 99%

Endovascular vs medical management of acute ischemic stroke

et al. 2015

View full text Add to dashboard Cite

show abstract

“…20,32 In subjects with M2 occlusion on baseline CTA, no significant difference in patency was identified on 24-hour CTA (88.5% in the EVT arm versus 76.5% in the IV tPA arm), but 90-day mRS 0 -2 outcomes were greater with EVT (n ϭ 31) than IV tPA alone (n ϭ 15) in M2 subjects with no ICA occlusion/stenosis, 51.6% versus 33.4%. 33 Reperfusion results were preliminarily reported here variously as mTICI 2-3 and/or 2b-3 to allow comparison with IMS I and II results of failed reperfusion versus outcome. Neither interobserver agreement in distinguishing 2a versus 2b reperfusion nor mTICI 2b-3 reperfusion as a predictor of good outcome for M2 occlusion had yet been shown.…”

mentioning

confidence: 99%

Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes

Tomsick

Carrozzella

Foster

et al. 2016

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…These improvements likely resulted in positive effect sizes where previous trials failed. In keeping with this, in a sub-analysis of IMS III, patients with documented occlusion who achieved recanalization within 6 h had a significant benefit [24]. All trials showed increased functional independence at 90 days with treatment with only one study, ESCAPE, showing significantly reduced mortality.…”

Section: Efficacy and Safetymentioning

confidence: 69%

An historical and contemporary review of endovascular therapy for acute ischemic stroke

2017

View full text Add to dashboard Cite

Long standing, evidence based approved therapies for acute ischemic stroke include intravenous thrombolysis therapy (IVT) with alteplase (recombinant tissue plasminogen activator, rtPA) given within 4.5 h; aspirin therapy within 48 h; management in an acute stroke unit and hemicraniectomy in cases of malignant infarction. Multiple recent positive randomized controlled trials (RCTs) have now also established endovascular therapy with mechanical thrombectomy as the standard of care for acute ischemic stroke involving a large vessel occlusion in the anterior circulation. This article will review the history of endovascular treatments for acute ischemic stroke and will review the recent positive and negative randomized controlled trial evidence for its efficacy. Current guidelines and dilemmas regarding appropriate patient selection will be discussed.

show abstract

Recanalization and Clinical Outcome of Occlusion Sites at Baseline CT Angiography in the Interventional Management of Stroke III Trial

Cited by 140 publications

References 23 publications

Endovascular vs medical management of acute ischemic stroke

Endovascular vs medical management of acute ischemic stroke

Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes

An historical and contemporary review of endovascular therapy for acute ischemic stroke

Contact Info

Product

Resources

About